Truncation of the TAR DNA-binding protein 43 is not a prerequisite for cytoplasmic relocalization, and is suppressed by caspase inhibition and by introduction of the A90V sequence variant

• Heike J. Wobst ,

  Contributed equally to this work with: Heike J. Wobst, Louise Delsing

  Affiliation AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America

  ⨯
• Louise Delsing ,

  Contributed equally to this work with: Heike J. Wobst, Louise Delsing

  Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, AstraZeneca, Discovery Science, Innovative Medicines and Early Development Biotech Unit, Mölndal, Sweden

  ⨯
• Nicholas J. Brandon,

  Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, AstraZeneca, Neuroscience, Innovative Medicines and Early Development, Waltham, MA, United States of America

  ⨯
• Stephen J. Moss

  * E-mail: Stephen.Moss@Tufts.edu

  Affiliations AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University, Boston, MA, United States of America, Department of Neuroscience, Tufts University School of Medicine, Boston, MA, United States of America

  ⨯